Multivariate analysis showed that the CYP2C19 phenotype PM and other risk factors (P2Y12 inhibitor [clopidogrel], body weight [> 50 kg], female, longer duration from onset to study treatment initiation, concomitant medications [proton pump inhibitor, calcium blocker, and angiotensin receptor blocker], and non-hypertension) were high-risk factors for HPR. Here, CYP2C19 is linked to Hypertension.